- Home
- CGON vs ICFI Comparison
CGON vs ICFI Comparison
Compare CGON & ICFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGON
- ICFI
- Stock Information
- Founded
- CGON 2010
- ICFI 1969
- Country
- CGON United States
- ICFI United States
- Employees
- CGON N/A
- ICFI N/A
- Industry
- CGON
- ICFI Professional Services
- Sector
- CGON
- ICFI Consumer Discretionary
- Exchange
- CGON NYSE
- ICFI Nasdaq
- Market Cap
- CGON 2.0B
- ICFI 1.6B
- IPO Year
- CGON 2024
- ICFI 2006
- Fundamental
- Price
- CGON $26.91
- ICFI $82.78
- Analyst Decision
- CGON Strong Buy
- ICFI Buy
- Analyst Count
- CGON 11
- ICFI 4
- Target Price
- CGON $63.30
- ICFI $115.50
- AVG Volume (30 Days)
- CGON 979.0K
- ICFI 141.1K
- Earning Date
- CGON 08-07-2025
- ICFI 07-31-2025
- Dividend Yield
- CGON N/A
- ICFI 0.68%
- EPS Growth
- CGON N/A
- ICFI 18.33
- EPS
- CGON N/A
- ICFI 5.82
- Revenue
- CGON $662,000.00
- ICFI $2,012,969,000.00
- Revenue This Year
- CGON N/A
- ICFI N/A
- Revenue Next Year
- CGON $21,843.29
- ICFI $1.54
- P/E Ratio
- CGON N/A
- ICFI $14.14
- Revenue Growth
- CGON 224.51
- ICFI 1.95
- 52 Week Low
- CGON $14.80
- ICFI $75.91
- 52 Week High
- CGON $40.47
- ICFI $179.67
- Technical
- Relative Strength Index (RSI)
- CGON 54.12
- ICFI 40.10
- Support Level
- CGON $25.14
- ICFI $82.96
- Resistance Level
- CGON $27.09
- ICFI $87.30
- Average True Range (ATR)
- CGON 1.50
- ICFI 2.23
- MACD
- CGON -0.04
- ICFI -0.32
- Stochastic Oscillator
- CGON 53.56
- ICFI 9.96
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
About ICFI ICF International Inc.
ICF International Inc provides professional services and technology-based solutions to government and commercial clients, including management, marketing, technology, and policy consulting and implementation services. Its services support clients that operate in four key markets that include Energy, Environment, Infrastructure and Disaster Recovery; Health and Social Programs and Security and Other Civilian & Commercial. The Company's majority clients are United States federal government departments and agencies. It operates in a single segment, which is providing professional services.